Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
investigational drug |
| gptkbp:CASNumber |
2419600-05-1
|
| gptkbp:clinicalTrialPhase |
Phase 2/3
|
| gptkbp:developedBy |
gptkb:Novartis
gptkb:Molecular_Partners |
| gptkbp:drugClass |
DARPin therapeutic
|
| gptkbp:hasINN |
gptkb:ensovibep
|
| https://www.w3.org/2000/01/rdf-schema#label |
ensovibep
|
| gptkbp:indication |
gptkb:COVID-19
|
| gptkbp:macromoleculeType |
protein therapeutic
|
| gptkbp:mechanismOfAction |
binds to spike protein of SARS-CoV-2
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:UNII |
1Q1J6Q6Q1B
|
| gptkbp:bfsParent |
gptkb:Molecular_Partners
|
| gptkbp:bfsLayer |
7
|